About Labrys Biologics
Labrys Biologics is a company based in San Mateo (United States) founded in 2012 was acquired by Teva Pharmaceuticals in June 2014.. Labrys Biologics has raised $31 million across 1 funding round from investors including Teva Pharmaceuticals, Canaan and venBio. Labrys Biologics operates in a competitive market with competitors including Alexion, argenx, BigHat, Flexion Therapeutics and Eliem Therapeutics, among others.
- Headquarter San Mateo, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$31 M (USD)
in 1 rounds
-
Latest Funding Round
$31 M (USD), Series A
Dec 28, 2012
-
Investors
Teva Pharmaceuticals
& 4 more
-
Employee Count
Employee Count
-
Acquired by
Teva Pharmaceuticals
(Jun 03, 2014)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Labrys Biologics
Labrys Biologics has successfully raised a total of $31M through 1 strategic funding round. The most recent funding activity was a Series A round of $31 million completed in December 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series A — $31.0M
-
First Round
First Round
(28 Dec 2012)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2012 | Amount | Series A - Labrys Biologics | Valuation | VenBio , Canaan |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Labrys Biologics
Labrys Biologics has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Teva Pharmaceuticals, Canaan and venBio. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
A life sciences investment firm focused on novel therapeutics is operated.
|
Founded Year | Domain | Location | |
|
Canaan is recognized as an early-stage venture capital firm.
|
Founded Year | Domain | Location | |
|
Early-stage investing in IT and healthcare ventures.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Labrys Biologics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Labrys Biologics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Labrys Biologics Comparisons
Competitors of Labrys Biologics
Labrys Biologics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alexion, argenx, BigHat, Flexion Therapeutics and Eliem Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapies for rare and devastating diseases are developed by Alexion.
|
|
| domain | founded_year | HQ Location |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment.
|
|
| domain | founded_year | HQ Location |
Antibody therapies are developed through machine learning and synthetic biology.
|
|
| domain | founded_year | HQ Location |
Developer of therapies for the treatment of musculoskeletal disorders
|
|
| domain | founded_year | HQ Location |
Develops antibody-based treatments for autoimmune and inflammatory disorders.
|
|
| domain | founded_year | HQ Location |
Therapeutics for retinal diseases are developed by the company.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Labrys Biologics
When was Labrys Biologics founded?
Labrys Biologics was founded in 2012.
Where is Labrys Biologics located?
Labrys Biologics is headquartered in San Mateo, United States. It is registered at San Mateo, California, United States.
Is Labrys Biologics a funded company?
Labrys Biologics is a funded company, having raised a total of $31M across 1 funding round to date. The company's 1st funding round was a Series A of $31M, raised on Dec 28, 2012.
What does Labrys Biologics do?
Labrys Biologics is a private, venture-financed development stage biotechnology company focused on treatments for chronic migraine and episodic migraine. It has acquired its lead candidate RN-307 from Pfizer, a Phase 2 ready anti-CGRP humanized monoclonal antibody for the treatment of a chronic migraine. RN-307 binds to calcitonin gene-related peptide (CGRP), a validated target in migraines. On June 3, 2014 Teva Pharmaceuticals acquired Labrys Biologics for upfront payment of 200M.
Who are the top competitors of Labrys Biologics?
Labrys Biologics's top competitors include argenx, Flexion Therapeutics and Kodiak Sciences.
Who are Labrys Biologics's investors?
Labrys Biologics has 5 investors. Key investors include Teva Pharmaceuticals, Canaan, venBio, InterWest, and Sofinnova.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.